These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3492613)

  • 21. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Severely contracted bladder following intravesical bacillus Calmette-Guérin therapy].
    Yoshimura K; Saiki S; Kuroda M; Kiyohara H; Kotake T
    Nihon Hinyokika Gakkai Zasshi; 1988 Nov; 79(11):1848-51. PubMed ID: 3216568
    [No Abstract]   [Full Text] [Related]  

  • 24. Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer.
    Oates RD; Stilmant MM; Freedlund MC; Siroky MB
    J Urol; 1988 Oct; 140(4):751-4. PubMed ID: 3418796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of blood group precursor T antigen as a prognostic marker for human bladder cancer treated by bacillus Calmette-Guerin and interleukin-2.
    Dow JA; di Sant'Agnese PA; Cockett AT
    J Urol; 1989 Oct; 142(4):978-81; discussion 981-2. PubMed ID: 2477561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulomatous inflammation in bladder wash specimens after intravesical bacillus Calmette-Guerin therapy for transitional cell carcinoma of the bladder.
    Betz SA; See WA; Cohen MB
    Am J Clin Pathol; 1993 Mar; 99(3):244-8. PubMed ID: 8447285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL; Thor DE; Harris SC; Reyna JA; Stogdill VD; Radwin HM
    J Urol; 1980 Jul; 124(1):38-40. PubMed ID: 6997513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic maltose tetrapalmitate and bacillus Calmette-Guerin immunotherapy of recurrent superficial bladder tumors: preliminary report.
    Ibrahiem EH; Ghoneim MA; Nigam V; Brailovsky C; Elhilali MM
    J Urol; 1988 Sep; 140(3):498-500. PubMed ID: 3411660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
    Soloway MS; Perry A
    J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
    Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
    J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
    Haase RN; Harving N
    Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
    [No Abstract]   [Full Text] [Related]  

  • 37. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ.
    Brosman SA
    J Urol; 1985 Jul; 134(1):36-9. PubMed ID: 3892049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.
    Böhle A; Nowc C; Ulmer AJ; Musehold J; Gerdes J; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):59-64. PubMed ID: 2193171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.